Revance Therapeutics (NASDAQ:RVNC – Get Rating) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a report issued on Monday.
A number of other research analysts have also recently commented on the stock. Cowen boosted their target price on shares of Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. Mizuho boosted their target price on shares of Revance Therapeutics from $26.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, September 9th. Barclays boosted their target price on shares of Revance Therapeutics from $22.00 to $35.00 and gave the stock an "overweight" rating in a research report on Friday, September 9th. Wells Fargo & Company boosted their target price on shares of Revance Therapeutics from $17.00 to $24.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 25th. Finally, Cowen boosted their target price on shares of Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $39.75.
Get Revance Therapeutics alerts:Revance Therapeutics Trading Down 2.3 %
Shares of RVNC stock opened at $26.01 on Monday. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -6.76 and a beta of 0.92. The company has a quick ratio of 3.20, a current ratio of 3.38 and a debt-to-equity ratio of 14.80. Revance Therapeutics has a fifty-two week low of $11.27 and a fifty-two week high of $30.00. The firm's 50 day moving average price is $20.27 and its two-hundred day moving average price is $17.40.
Revance Therapeutics (NASDAQ:RVNC – Get Rating) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.91) by $0.03. The firm had revenue of $28.37 million for the quarter, compared to analysts' expectations of $27.64 million. Revance Therapeutics had a negative net margin of 265.04% and a negative return on equity of 497.77%. On average, analysts anticipate that Revance Therapeutics will post -3.69 EPS for the current year.Insider Buying and Selling
In related news, SVP Dwight Moxie sold 11,000 shares of Revance Therapeutics stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $27.07, for a total value of $297,770.00. Following the completion of the sale, the senior vice president now owns 31,694 shares in the company, valued at $857,956.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.10% of the company's stock.
Institutional Trading of Revance Therapeutics
Several institutional investors have recently added to or reduced their stakes in RVNC. Dimensional Fund Advisors LP increased its stake in Revance Therapeutics by 7.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 131,661 shares of the biopharmaceutical company's stock valued at $2,149,000 after purchasing an additional 8,801 shares during the last quarter. Teacher Retirement System of Texas increased its stake in Revance Therapeutics by 18.6% during the fourth quarter. Teacher Retirement System of Texas now owns 12,940 shares of the biopharmaceutical company's stock valued at $211,000 after purchasing an additional 2,032 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in Revance Therapeutics during the fourth quarter valued at $175,000. Rafferty Asset Management LLC increased its stake in Revance Therapeutics by 88.7% during the fourth quarter. Rafferty Asset Management LLC now owns 14,724 shares of the biopharmaceutical company's stock valued at $240,000 after purchasing an additional 6,923 shares during the last quarter. Finally, MAI Capital Management bought a new stake in Revance Therapeutics during the fourth quarter valued at $193,000. Institutional investors own 77.08% of the company's stock.
About Revance Therapeutics
(Get Rating)
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Read More
- Get a free copy of the StockNews.com research report on Revance Therapeutics (RVNC)
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.